BidaskClub downgraded shares of Entellus Medical (NASDAQ:ENTL) from a sell rating to a strong sell rating in a report issued on Saturday.
Several other equities research analysts also recently weighed in on the company. William Blair downgraded Entellus Medical from an outperform rating to a market perform rating in a report on Friday, December 8th. ValuEngine upgraded Entellus Medical from a sell rating to a hold rating in a report on Thursday, December 7th. Zacks Investment Research downgraded Entellus Medical from a buy rating to a hold rating in a report on Tuesday, October 31st. Finally, TheStreet upgraded Entellus Medical from a d rating to a c- rating in a report on Thursday, December 14th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The company has an average rating of Hold and a consensus price target of $19.25.
Shares of Entellus Medical (NASDAQ ENTL) opened at $24.06 on Friday. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $25.58. The firm has a market capitalization of $619.02, a PE ratio of -18.65 and a beta of -0.02.
In other news, VP Thomas P. Williamson sold 2,449 shares of the stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $24.08, for a total value of $58,971.92. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Robert S. White sold 3,471 shares of the stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $24.01, for a total value of $83,338.71. The disclosure for this sale can be found here. In the last quarter, insiders sold 108,942 shares of company stock worth $2,599,658. Company insiders own 7.70% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ENTL. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Entellus Medical in the 4th quarter valued at about $105,000. MetLife Investment Advisors LLC acquired a new stake in shares of Entellus Medical in the 4th quarter valued at about $152,000. Nationwide Fund Advisors boosted its position in shares of Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 2,635 shares during the period. Alliancebernstein L.P. acquired a new stake in shares of Entellus Medical in the 4th quarter valued at about $224,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Entellus Medical by 145.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock valued at $168,000 after purchasing an additional 5,605 shares during the period. Institutional investors and hedge funds own 75.67% of the company’s stock.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.